Skip to main content
SpringerLink
Log in

Bacteria

  • Chapter
  • First Online:
Managing Infections in Patients With Hematological Malignancies

Part of the book series: Contemporary Hematology ((CH))

  • 644 Accesses

Abstract

Despite the fact that survival among patients with hematologic malignancies has considerably improved, bacterial infections continue to occur as a result of prolonged, profound immunosuppression. Neutropenia, vascular catheters, and chemotherapy-induced mucositis are key risk factors. Data on blood stream infections show the predominance of aerobic gram-positive cocci; however, gram-negative bacilli continue to play a significant role. Better microbiologic data on tissue site infections are needed. Rapid molecular methods of microbiologic diagnosis are entering clinical practice. In an era of ever fewer new antimicrobial drugs developed by pharmaceutical companies, the rising frequency of drug-resistant pathogens among staphylococci, streptococci, enterococci, and aerobic gram-negative bacteria in cancer patients is alarming. Prudent use of available antimicrobial drugs is ever more critical to stem the tide of antibiotic-resistant bacteria.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB (2003) Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36:1103–1110

    PubMed  Google Scholar 

  2. Yadegarynia D, Tarrand J, Raad I, Rolston K (2003) Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 37(8):1144–1145

    PubMed  CAS  Google Scholar 

  3. Cherif H, Kronvall G, Bjorkholm M, Kalin M (2003) Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J 4:420–426

    PubMed  Google Scholar 

  4. Lowder JN, Lazarus HM, Herzig RH (1982) Bacteremias and fungemias in oncologic patients with central venous catheters: changing spectrum of infection. Arch Intern Med 142:1456–1459

    PubMed  CAS  Google Scholar 

  5. Viscoli C, Bruzzi P, Castagnola E et al (1994) Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 30A:430–437

    PubMed  CAS  Google Scholar 

  6. Rotstein C, Mandell L, Goldberg N (1997) Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta-analysis. Curr Oncol 4:S2–S7

    Google Scholar 

  7. Engels EA, Lau J, Barza M (1998) Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16:1179–1187

    PubMed  CAS  Google Scholar 

  8. Elting LS, Bodey GP, Keefe BH (1992) Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 14:1201–1207

    PubMed  CAS  Google Scholar 

  9. Rolston KV, Yadegarynia D, Kontoyiannis DP, Raad II, Ho DH (2006) The spectrum of gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients. Int J Infect Dis 10:223–230

    PubMed  CAS  Google Scholar 

  10. Schwalbe RS, Stapleton JT, Gilligan PH (1987) Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 316:927–931

    PubMed  CAS  Google Scholar 

  11. Biavasco F, Vignaroli C, Varaldo PE (2000) Glycopeptide resistance in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 19:403–417

    PubMed  CAS  Google Scholar 

  12. Sieradzki K, Villari P, Tomasz A (1998) Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 42:100–107

    PubMed  CAS  Google Scholar 

  13. Falcone M, Micozzi A, Pompeo ME et al (2004) Methicillin-resistant staphylococcal bacteremia in patients with hematologic malignancies: clinical and microbiological retrospective comparative analysis of S. haemolyticus, S. epidermidis and S. aureus. J Chemother 16:540–548

    Google Scholar 

  14. Diekema DJ, Pfaller MA, Jones RN (2002) Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997–2000. Int J Antimicrob Agents 20:412–418

    PubMed  CAS  Google Scholar 

  15. Wisplinghoff H, Cornely OA, Moser S et al (2003) Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study. Infect Control Hosp Epidemiol 24:905–911

    PubMed  Google Scholar 

  16. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309–317

    PubMed  Google Scholar 

  17. Fowler VG Jr, Olsen MK, Corey GR et al (2003) Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 163:2066–2072

    PubMed  Google Scholar 

  18. Ghanem GA, Boktour M, Warneke C et al (2007) Catheter-related Staphylococcus aureus bacteremia in cancer patients: high rate of complications with therapeutic implications. Medicine (Baltimore) 86:54–60

    Google Scholar 

  19. Venditti M, Falcone M, Micozzi A et al (2003) Staphylococcus aureus bacteremia in patients with hematologic malignancies: a retrospective case-control study. Haematologica 88:923–930

    PubMed  Google Scholar 

  20. Chambers HF (2005) Community-associated MRSA – resistance and virulence converge. N Engl J Med 352:1485–1487

    PubMed  CAS  Google Scholar 

  21. Fridkin SK, Hageman JC, Morrison M et al (2005) Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 352:1436–1444

    PubMed  CAS  Google Scholar 

  22. Weber JT (2005) Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 41(Suppl 4):S269–S272

    PubMed  CAS  Google Scholar 

  23. Jauregui LE, Babazadeh S, Seltzer E et al (2005) Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 41:1407–1415

    PubMed  CAS  Google Scholar 

  24. Stryjewski ME, Chu VH, O’Riordan WD et al (2006) Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 50:862–867

    PubMed  CAS  Google Scholar 

  25. Tenover FC, Lancaster MV, Hill BC et al (1998) Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 36:1020–1027

    PubMed  CAS  Google Scholar 

  26. Moore MR, Perdreau-Remington F, Chambers HF (2003) Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 47:1262–1266

    PubMed  CAS  Google Scholar 

  27. Howden BP, Ward PB, Charles PG et al (2004) Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38:521–528

    PubMed  CAS  Google Scholar 

  28. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML (2004) Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38:448–451

    PubMed  Google Scholar 

  29. Richard P, Amador Del Valle G, Moreau P et al (1995) Viridans streptococcal bacteraemia in patients with neutropenia. Lancet 345:1607–1609

    PubMed  CAS  Google Scholar 

  30. Tunkel AR, Sepkowitz KA (2002) Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 34:1524–1529

    PubMed  Google Scholar 

  31. Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R (2002) Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 34:1469–1474

    PubMed  CAS  Google Scholar 

  32. Han XY, Kamana M, Rolston KV (2006) Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases. J Clin Microbiol 44:160–165

    PubMed  Google Scholar 

  33. Alcaide F, Benitez MA, Carratala J, Gudiol F, Linares J, Martin R (2001) In vitro activities of the new ketolide HMR 3647 (telithromycin) in comparison with those of eight other antibiotics against viridans group Streptococci isolated from blood of neutropenic patients with cancer. Antimicrob Agents Chemother 45:624–626

    PubMed  CAS  Google Scholar 

  34. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL (1996) Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 40:891–894

    PubMed  CAS  Google Scholar 

  35. Marron A, Carratala J, Gonzalez-Barca E, Fernandez-Sevilla A, Alcaide F, Gudiol F (2000) Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer. Clin Infect Dis 31:1126–1130

    PubMed  CAS  Google Scholar 

  36. Whiley RA, Fraser HY, Douglas CW, Hardie JM, Williams AM, Collins MD (1990) Streptococcus parasanguis sp. nov., an atypical viridans Streptococcus from human clinical specimens. FEMS Microbiol Lett 56:115–121

    PubMed  CAS  Google Scholar 

  37. Kumashi P, Girgawy E, Tarrand JJ, Rolston KV, Raad II, Safdar A (2005) Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998-2002). Medicine (Baltimore) 84:303–312

    Google Scholar 

  38. Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A (2007) Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989–2005. Medicine (Baltimore) 86:69–77

    Google Scholar 

  39. DiazGranados CA, Jernigan JA (2005) Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 191:588–595

    PubMed  CAS  Google Scholar 

  40. Vergis EN, Hayden MK, Chow JW et al (2001) Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med 135:484–492

    PubMed  CAS  Google Scholar 

  41. Garbutt JM, Ventrapragada M, Littenberg B, Mundy LM (2000) Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis 30:466–472

    PubMed  CAS  Google Scholar 

  42. Venditti M, Tarasi A, Visco Comandini U et al (1993) Enterococcal septicemia in patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 12:241–247

    PubMed  CAS  Google Scholar 

  43. Todeschini G, Tecchio C, Borghero C et al (2006) Association between Enterococcus bacteraemia and death in neutropenic patients with haematological malignancies. J Infect 53:266–273

    PubMed  Google Scholar 

  44. Morris JG Jr, Shay DK, Hebden JN et al (1995) Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 123:250–259

    PubMed  CAS  Google Scholar 

  45. Matar MJ, Tarrand J, Raad I, Rolston KV (2006) Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control 34:534–536

    PubMed  Google Scholar 

  46. Hachem R, Graviss L, Hanna H et al (2004) Impact of surveillance for vancomycin-resistant enterococci on controlling a bloodstream outbreak among patients with hematologic malignancy. Infect Control Hosp Epidemiol 25:391–394

    PubMed  Google Scholar 

  47. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE Jr, Archibald LK, Gaynes RP, Tenover FC (1999) Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 29(2):245–252

    PubMed  CAS  Google Scholar 

  48. Ostrowsky BE, Trick WE, Sohn AH, Quirk SB, Holt S, Carson LA, Hill BC, Arduino MJ, Kuehnert MJ, Jarvis WR (2001) Control of vancomycin-resistant enterococcus in health care facilities in a region. N Engl J Med 344(19):1427–1433

    PubMed  CAS  Google Scholar 

  49. Price CS, Paule S, Noskin GA, Peterson LR (2003) Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis 37:921–928

    PubMed  Google Scholar 

  50. Montecalvo MA, Jarvis WR, Uman J et al (1999) Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med 131:269–272

    PubMed  CAS  Google Scholar 

  51. Dubberke ER, Hollands JM, Georgantopoulos P et al (2006) Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transplant 38:813–819

    PubMed  CAS  Google Scholar 

  52. Avery R, Kalaycio M, Pohlman B et al (2005) Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant 35:497–499

    PubMed  CAS  Google Scholar 

  53. Mylonakis E, Hohmann EL, Calderwood SB (1998) Central nervous system infection with Listeria monocytogenes. 33 years’ experience at a general hospital and review of 776 episodes from the literature. Medicine (Baltimore) 77:313–336

    CAS  Google Scholar 

  54. Mylonakis E, Paliou M, Hohmann EL, Calderwood SB, Wing EJ (2002) Listeriosis during pregnancy: a case series and review of 222 cases. Medicine (Baltimore) 81:260–269

    Google Scholar 

  55. Armstrong RW, Fung PC (1993) Brainstem encephalitis (rhombencephalitis) due to Listeria monocytogenes: case report and review. Clin Infect Dis 16:689–702

    PubMed  CAS  Google Scholar 

  56. Lorber B (1997) Listeriosis. Clin Infect Dis 24:1–9 quiz 10-1

    PubMed  CAS  Google Scholar 

  57. Safdar A, Papadopoulous EB, Armstrong D (2002) Listeriosis in recipients of allogeneic blood and marrow transplantation: thirteen year review of disease characteristics, treatment outcomes and a new association with human cytomegalovirus infection. Bone Marrow Transplant 29:913–916

    PubMed  CAS  Google Scholar 

  58. Decker CF, Simon GL, DiGioia RA, Tuazon CU (1991) Listeria monocytogenes infections in patients with AIDS: report of five cases and review. Rev Infect Dis 13:413–417

    PubMed  CAS  Google Scholar 

  59. Hantel A, Dick JD, Karp JE (1989) Listeriosis in the setting of malignant disease. Changing issues in an unusual infection. Cancer 64:516–520

    PubMed  CAS  Google Scholar 

  60. Jensen A, Frederiksen W, Gerner-Smidt P (1994) Risk factors for listeriosis in Denmark, 1989–1990. Scand J Infect Dis 26:171–178

    PubMed  CAS  Google Scholar 

  61. Rivero GA, Torres HA, Rolston KV, Kontoyiannis DP (2003) Listeria monocytogenes infection in patients with cancer. Diagn Microbiol Infect Dis 47:393–398

    PubMed  CAS  Google Scholar 

  62. Vazquez-Boland JA, Kuhn M, Berche P et al (2001) Listeria pathogenesis and molecular virulence determinants. Clin Microbiol Rev 14:584–640

    PubMed  CAS  Google Scholar 

  63. Anaissie E, Kontoyiannis DP, Kantarjian H, Elting L, Robertson LE, Keating M (1992) Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 117:466–469

    PubMed  CAS  Google Scholar 

  64. Anaissie EJ, Kontoyiannis DP, O’Brien S et al (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129:559–566

    PubMed  CAS  Google Scholar 

  65. Safdar A, Armstrong D (2003) Antimicrobial activities against 84 Listeria monocytogenes isolates from patients with systemic listeriosis at a comprehensive cancer center (1955–1997). J Clin Microbiol 41:483–485

    PubMed  CAS  Google Scholar 

  66. Girmenia C, Iori AP, Bernasconi S, Testi AM, Moleti ML, Arcese W, Martino P (2000) Listeriosis in recipients of allogeneic bone marrow transplants from unrelated donors. Eur J Clin Microbiol Infect Dis 19(9):711–714

    PubMed  CAS  Google Scholar 

  67. Velasco E, Byington R, Martins CA, Schirmer M, Dias LM, Goncalves VM (2006) Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections. Eur J Clin Microbiol Infect Dis 25:1–7

    PubMed  CAS  Google Scholar 

  68. Chen CY, Tang JL, Hsueh PR et al (2004) Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy. J Formos Med Assoc 103:526–532

    PubMed  CAS  Google Scholar 

  69. Hughes WT, Armstrong D, Bodey GP et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751

    PubMed  Google Scholar 

  70. McGowan JE Jr (2006) Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Infect Control 34:S29–S37 discussion S64 –73

    PubMed  Google Scholar 

  71. Gunther G, Bjorkholm M, Bjorklind A, Engervall P, Stiernstedt G (1991) Septicemia in patients with hematological disorders and neutropenia. A retrospective study of causative agents and their resistance profile. Scand J Infect Dis 23:589–598

    PubMed  CAS  Google Scholar 

  72. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R (1994) Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38:681–687

    PubMed  CAS  Google Scholar 

  73. Cometta A, Calandra T, Bille J, Glauser MP (1994) Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 330:1240–1241

    PubMed  CAS  Google Scholar 

  74. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F (1995) Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 20:557–560 discussion 61–3

    PubMed  CAS  Google Scholar 

  75. Cruciani M, Rampazzo R, Malena M et al (1996) Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23:795–805

    PubMed  CAS  Google Scholar 

  76. Murphy M, Brown AE, Sepkowitz KA, Bernard EM, Kiehn TE, Armstrong D (1997) Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer – is it justified? Clin Infect Dis 25:346–348

    PubMed  CAS  Google Scholar 

  77. Kern WV, Klose K, Jellen-Ritter AS et al (2005) Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 24:111–118

    PubMed  CAS  Google Scholar 

  78. Reuter S, Kern WV, Sigge A et al (2005) Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 40:1087–1093

    PubMed  CAS  Google Scholar 

  79. Cullen M, Steven N, Billingham L et al (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988–998

    PubMed  CAS  Google Scholar 

  80. Bucaneve G, Micozzi A, Menichetti F et al (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977–987

    PubMed  CAS  Google Scholar 

  81. Kirby JT, Fritsche TR, Jones RN (2006) Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America). Diagn Microbiol Infect Dis 56:75–82

    PubMed  CAS  Google Scholar 

  82. Mutnick AH, Kirby JT, Jones RN (2003) CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance. Ann Pharmacother 37:47–56

    PubMed  CAS  Google Scholar 

  83. Safdar N, Maki DG (2002) The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 136:834–844

    PubMed  Google Scholar 

  84. Paterson DL (2006) Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control 34:S20–S28 discussion S64 –73

    PubMed  Google Scholar 

  85. Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ (2006) Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther 4:9–25

    PubMed  CAS  Google Scholar 

  86. Spanik S, Trupl J, Kunova A et al (1996) Bloodstream infections due to anaerobic bacteria in cancer patients: epidemiology, etiology, risk factors, clinical presentation and outcome of anaerobic bacteremia. Neoplasma 43:235–238

    PubMed  CAS  Google Scholar 

  87. Krcmery V, Spanik S, Mrazova M et al (2002) Bacteremias caused by Escherichia coli in cancer patients – analysis of 65 episodes. Int J Infect Dis 6:69–73

    PubMed  Google Scholar 

  88. Watson JT, Jones RC, Siston AM et al (2005) Outbreak of catheter-associated Klebsiella oxytoca and Enterobacter cloacae bloodstream infections in an oncology chemotherapy center. Arch Intern Med 165:2639–2643

    PubMed  Google Scholar 

  89. Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40:1333–1341

    PubMed  CAS  Google Scholar 

  90. Antoniadou A, Kontopidou F, Poulakou G et al (2007) Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 59:786–790

    PubMed  CAS  Google Scholar 

  91. Gaynes R, Edwards JR (2005) Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41:848–854

    PubMed  Google Scholar 

  92. Maschmeyer G, Braveny I (2000) Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis 19:915–925

    PubMed  CAS  Google Scholar 

  93. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G (2000) Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 160:501–509

    PubMed  CAS  Google Scholar 

  94. Pier G, Ramphal R (2005) Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas and Bennett’s Principles and practice of infectious diseases, 6th edn. Elsevier Churchill Livingston, Philadelphia, PA, pp 2567–2615

    Google Scholar 

  95. Bodey GP, Jadeja L, Elting L (1985) Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 145:1621–1629

    PubMed  CAS  Google Scholar 

  96. Verhagen C, de Pauw BE, Donnelly JP, Williams KJ, de Witte T, Janssen TH (1986) Ceftazidime alone for treating Pseudomonas aeruginosa septicaemia in neutropenic patients. J Infect 13:125–131

    PubMed  CAS  Google Scholar 

  97. Chamot E, Boffi El Amari E, Rohner P, Van Delden C (2003) Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 47:2756–64

    PubMed  CAS  Google Scholar 

  98. (2007) Prevention and treatment of cancer-related infections. http://www.nccn.org. Accessed V.I.2007

  99. Carratalà J, Rosón B, Fernández-Sevilla A, Alcaide F, Gudiol F (1998) Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch Intern Med 158(8):868–872

    PubMed  Google Scholar 

  100. Todeschini G, Franchini M, Tecchio C et al (1998) Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies. Int J Infect Dis 3:99–104

    PubMed  Google Scholar 

  101. Maschmeyer G, Noskin GA, Ribaud P, Sepkowitz KA (2000) Changing patterns of infections and antimicrobial susceptibilities. Oncology 14:9–16

    PubMed  CAS  Google Scholar 

  102. Jacobson K, Rolston K, Elting L, LeBlanc B, Whimbey E, Ho DH (1999) Suscep­tibility surveillance among gram-negative bacilli at a cancer center. Chemotherapy 45:325–334

    PubMed  CAS  Google Scholar 

  103. Ohmagari N, Hanna H, Graviss L et al (2005) Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 104:205–212

    PubMed  Google Scholar 

  104. Tascini C, Menichetti F, Stefanelli A, Loni C, Lambelet P (2006) Clinical efficacy of intravenous colistin therapy in combination with ceftazidime in severe MDR P. aeruginosa systemic infections in two haematological patients. Infez Med 14:41–44

    PubMed  CAS  Google Scholar 

  105. Micol JB, de Botton S, Guieze R et al (2006) An 18-case outbreak of drug-resistant Pseudomonas aeruginosa bacteriemia in hematology patients. Haematologica 91:1134–1138

    PubMed  CAS  Google Scholar 

  106. Landman D, Bratu S, Alam M, Quale J (2005) Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 55:954–957

    PubMed  CAS  Google Scholar 

  107. Beno P, Krcmery V, Demitrovicova A (2006) Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin. Clin Microbiol Infect 12:497–498

    PubMed  CAS  Google Scholar 

  108. Micozzi A, Venditti M, Monaco M et al (2000) Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis 31:705–711

    PubMed  CAS  Google Scholar 

  109. Victor MA, Arpi M, Bruun B, Jonsson V, Hansen MM (1994) Xanthomonas maltophilia bacteremia in immunocompromised hematological patients. Scand J Infect Dis 26:163–170

    PubMed  CAS  Google Scholar 

  110. Krcmery V Jr, Pichna P, Oravcova E et al (1996) Stenotrophomonas maltophilia bacteraemia in cancer patients: report on 31 cases. J Hosp Infect 34:75–77

    PubMed  Google Scholar 

  111. Elting LS, Bodey GP (1990) Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine (Baltimore) 69:296–306

    CAS  Google Scholar 

  112. Khardori N, Elting L, Wong E, Schable B, Bodey GP (1990) Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 12:997–1003

    PubMed  CAS  Google Scholar 

  113. Apisarnthanarak A, Mayfield JL, Garison T et al (2003) Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Infect Control Hosp Epidemiol 24:269–274

    PubMed  Google Scholar 

  114. Boktour M, Hanna H, Ansari S et al (2006) Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients. Cancer 106:1967–1973

    PubMed  Google Scholar 

  115. Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW (2002) Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect 45:47–53

    PubMed  CAS  Google Scholar 

  116. Muder RR, Harris AP, Muller S et al (1996) Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 22:508–512

    PubMed  CAS  Google Scholar 

  117. Elting LS, Khardori N, Bodey GP, Fainstein V (1990) Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol 11:134–138

    PubMed  CAS  Google Scholar 

  118. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ (2005) In vitro activity of tigecycline against 6792 gram-negative and gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 52:215–227

    PubMed  CAS  Google Scholar 

  119. Sanders WE Jr, Sanders CC (1997) Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev 10:220–241

    PubMed  Google Scholar 

  120. Bodey GP, Elting LS, Rodriguez S (1991) Bacteremia caused by Enterobacter: 15 years of experience in a cancer hospital. Rev Infect Dis 13:550–558

    PubMed  CAS  Google Scholar 

  121. Chow JW, Fine MJ, Shlaes DM et al (1991) Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 115:585–590

    PubMed  CAS  Google Scholar 

  122. Seifert H, Strate A, Pulverer G (1995) Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 74:340–349

    CAS  Google Scholar 

  123. Bergogne-Berezin E, Towner KJ (1996) Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9:148–165

    PubMed  CAS  Google Scholar 

  124. Cisneros JM, Reyes MJ, Pachon J et al (1996) Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 22:1026–1032

    PubMed  CAS  Google Scholar 

  125. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H (2000) Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 31:690–697

    PubMed  CAS  Google Scholar 

  126. Koprnova J, Svetlansky I, Babel’a R et al (2001) Prospective study of antibacterial susceptibility, risk factors and outcome of 157 episodes of Acinetobacter baumannii bacteremia in 1999 in Slovakia. Scand J Infect Dis 33:891–895

    PubMed  CAS  Google Scholar 

  127. Chen HP, Chen TL, Lai CH et al (2005) Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 38:127–136

    PubMed  Google Scholar 

  128. Hernandez JA, Martino R, Pericas R, Sureda A, Brunet S, Domingo-Albos A (1998) Achromobacter xylosoxidans bacteremia in patients with hematologic malignancies. Haematologica 83:284–285

    PubMed  CAS  Google Scholar 

  129. Legrand C, Anaissie E (1992) Bacteremia due to Achromobacter xylosoxidans in patients with cancer. Clin Infect Dis 14:479–484

    PubMed  CAS  Google Scholar 

  130. Duggan JM, Goldstein SJ, Chenoweth CE, Kauffman CA, Bradley SF (1996) Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Clin Infect Dis 23:569–576

    PubMed  CAS  Google Scholar 

  131. Aisenberg G, Rolston KV, Safdar A (2004) Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989–2003). Cancer 101:2134–2140

    PubMed  Google Scholar 

  132. Tsai MS, Kuo CY, Wang MC, Wu HC, Chien CC, Liu JW (2006) Clinical features and risk factors for mortality in Aeromonas bacteremic adults with hematologic malignancies. J Microbiol Immunol Infect 39:150–154

    PubMed  Google Scholar 

  133. De I, Rolston KV, Han XY (2004) Clinical significance of Roseomonas species isolated from catheter and blood samples: analysis of 36 cases in patients with cancer. Clin Infect Dis 38:1579–1584

    PubMed  Google Scholar 

  134. Han XY, Tarrand JJ (2004) Moraxella osloensis blood and catheter infections during anticancer chemotherapy: clinical and microbiologic studies of 10 cases. Am J Clin Pathol 121:581–587

    PubMed  Google Scholar 

  135. McDonald LC, Owings M, Jernigan DB (2006) Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis 12:409–415

    PubMed  Google Scholar 

  136. Bignardi GE (1998) Risk factors for Clostridium difficile infection. J Hosp Infect 40:1–15

    PubMed  CAS  Google Scholar 

  137. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC (2000) Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 38:2386–2388

    PubMed  CAS  Google Scholar 

  138. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D (2004) Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 171:33–38

    PubMed  Google Scholar 

  139. Dial S, Delaney JA, Barkun AN, Suissa S (2005) Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294:2989–2995

    PubMed  CAS  Google Scholar 

  140. Gaynes R, Rimland D, Killum E et al (2004) Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 38:640–645

    PubMed  Google Scholar 

  141. Muto CA, Pokrywka M, Shutt K et al (2005) A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 26:273–280

    PubMed  Google Scholar 

  142. Pepin J, Saheb N, Coulombe MA et al (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41:1254–1260

    PubMed  CAS  Google Scholar 

  143. Loo VG, Poirier L, Miller MA et al (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353:2442–2449

    PubMed  CAS  Google Scholar 

  144. Gifford AH, Kirkland KB (2006) Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward. Eur J Clin Microbiol Infect Dis 25:751–755

    PubMed  CAS  Google Scholar 

  145. Palmore TN, Sohn S, Malak SF, Eagan J, Sepkowitz KA (2005) Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol 26:680–684

    PubMed  Google Scholar 

  146. Blot E, Escande MC, Besson D et al (2003) Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect 53:187–192

    PubMed  CAS  Google Scholar 

  147. Gorschluter M, Glasmacher A, Hahn C et al (2001) Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 33:786–791

    PubMed  CAS  Google Scholar 

  148. Hornbuckle K, Chak A, Lazarus HM et al (1998) Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients. Ann Oncol 9:307–311

    PubMed  CAS  Google Scholar 

  149. Gerard M, Defresne N, Daneau D et al (1988) Incidence and significance of Clostridium difficile in hospitalized cancer patients. Eur J Clin Microbiol Infect Dis 7:274–278

    PubMed  CAS  Google Scholar 

  150. Heard SR, Wren B, Barnett MJ, Thomas JM, Tabaqchali S (1988) Clostridium difficile infection in patients with haematological malignant disease. Risk factors, faecal toxins and pathogenic strains. Epidemiol Infect 100:63–72

    PubMed  CAS  Google Scholar 

  151. Panichi G, Pantosti A, Gentile G et al (1985) Clostridium difficile colitis in leukemia patients. Eur J Cancer Clin Oncol 21:1159–1163

    PubMed  CAS  Google Scholar 

  152. Rampling A, Warren RE, Bevan PC, Hoggarth CE, Swirsky D, Hayhoe FG (1985) Clostridium difficile in haematological malignancy. J Clin Pathol 38:445–451

    PubMed  CAS  Google Scholar 

  153. Morris JG Jr, Jarvis WR, Nunez-Montiel OL et al (1984) Clostridium difficile. Colonization and toxin production in a cohort of patients with malignant hematologic disorders. Arch Intern Med 144:967–969

    PubMed  Google Scholar 

  154. Cudmore MA, Silva J Jr, Fekety R, Liepman MK, Kim KH (1982) Clostridium difficile colitis associated with cancer chemotherapy. Arch Intern Med 142:333–335

    PubMed  CAS  Google Scholar 

  155. Anand A, Glatt AE (1993) Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 17:109–113

    PubMed  CAS  Google Scholar 

  156. Chakrabarti S, Lees A, Jones SG, Milligan DW (2000) Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. Bone Marrow Transplant 26:871–876

    PubMed  CAS  Google Scholar 

  157. Husain A, Aptaker L, Spriggs DR, Barakat RR (1998) Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol 71:104–107

    PubMed  CAS  Google Scholar 

  158. Emoto M, Kawarabayashi T, Hachisuga MD, Eguchi F, Shirakawa K (1996) Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol 61:369–372

    PubMed  CAS  Google Scholar 

  159. McDonald LC, Killgore GE, Thompson A et al (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353:2433–2441

    PubMed  CAS  Google Scholar 

  160. Pepin J, Valiquette L, Alary ME et al (2004) Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171:466–472

    PubMed  Google Scholar 

  161. Dallal RM, Harbrecht BG, Boujoukas AJ et al (2002) Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 235:363–372

    PubMed  Google Scholar 

  162. Bartlett JG, Perl TM (2005) The new Clostridium difficile – what does it mean? N Engl J Med 353:2503–2505

    PubMed  CAS  Google Scholar 

  163. Warny M, Pepin J, Fang A et al (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079–1084

    PubMed  CAS  Google Scholar 

  164. Spigaglia P, Mastrantonio P (2002) Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 40:3470–3475

    PubMed  CAS  Google Scholar 

  165. Dubberke ER, Sadhu J, Gatti R et al (2007) Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system. Infect Control Hosp Epidemiol 28:208–211

    PubMed  Google Scholar 

  166. Sunenshine RH, McDonald LC (2006) Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 73:187–197

    PubMed  Google Scholar 

  167. Bartlett JG (2006) Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 145:758–764

    PubMed  Google Scholar 

  168. Mohan SS, McDermott BP, Parchuri S, Cunha BA (2006) Lack of value of repeat stool testing for Clostridium difficile toxin. Am J Med 119:356.e7–356.e8

    Google Scholar 

  169. Arango JI, Restrepo A, Schneider DL et al (2006) Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 37:517–521

    PubMed  CAS  Google Scholar 

  170. Gerding DN (2005) Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin Infect Dis 40:1598–1600

    PubMed  CAS  Google Scholar 

  171. Apisarnthanarak A, Razavi B, Mundy LM (2002) Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 35:690–696

    PubMed  Google Scholar 

  172. Lipsett PA, Samantaray DK, Tam ML, Bartlett JG, Lillemoe KD (1994) Pseudomembranous colitis: a surgical disease? Surgery 116:491–496

    PubMed  CAS  Google Scholar 

  173. Koss K, Clark MA, Sanders DS, Morton D, Keighley MR, Goh J (2006) The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis 8:149–154

    PubMed  CAS  Google Scholar 

  174. Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE (2004) Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 47:1620–1626

    PubMed  Google Scholar 

  175. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME (1997) Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 24:324–333

    PubMed  CAS  Google Scholar 

  176. McFarland LV, Elmer GW, Surawicz CM (2002) Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97:1769–1775

    PubMed  CAS  Google Scholar 

  177. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN (2007) Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 44:846–848

    PubMed  CAS  Google Scholar 

  178. Dendukuri N, Costa V, McGregor M, Brophy JM (2005) Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 173:167–170

    PubMed  Google Scholar 

  179. McFarland LV (2006) Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 101:812–822

    PubMed  Google Scholar 

  180. Mogg GA, George RH, Youngs D et al (1982) Randomized controlled trial of colestipol in antibiotic-associated colitis. Br J Surg 69:137–139

    PubMed  CAS  Google Scholar 

  181. Aas J, Gessert CE, Bakken JS (2003) Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36:580–585

    PubMed  Google Scholar 

  182. Aboudola S, Kotloff KL, Kyne L et al (2003) Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 71:1608–1610

    PubMed  CAS  Google Scholar 

  183. McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ (2006) Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 49:640–645

    PubMed  Google Scholar 

  184. Musher DM, Logan N, Hamill RJ et al (2006) Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 43:421–427

    PubMed  CAS  Google Scholar 

  185. Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, Dow G, Weiss K, Simon S, John JF Jr, Garber G, Chasan-Taber S, Davidson DM, Tolevamer Study Investigator Group (2006) Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 43(4):411–420

    PubMed  CAS  Google Scholar 

  186. McNeil MM, Brown JM (1994) The medically important aerobic actinomycetes: epidemiology and microbiology. Clin Microbiol Rev 7:357–417

    PubMed  CAS  Google Scholar 

  187. Torres HA, Reddy BT, Raad II et al (2002) Nocardiosis in cancer patients. Medicine (Baltimore) 81:388–397

    CAS  Google Scholar 

  188. van Burik JA, Hackman RC, Nadeem SQ et al (1997) Nocardiosis after bone marrow transplantation: a retrospective study. Clin Infect Dis 24:1154–1160

    PubMed  Google Scholar 

  189. Choucino C, Goodman SA, Greer JP, Stein RS, Wolff SN, Dummer JS (1996) Nocardial infections in bone marrow transplant recipients. Clin Infect Dis 23:1012–1019

    PubMed  CAS  Google Scholar 

  190. Daly AS, McGeer A, Lipton JH (2003) Systemic nocardiosis following allogeneic bone marrow transplantation. Transpl Infect Dis 5:16–20

    PubMed  CAS  Google Scholar 

  191. Samonis G, Kontoyiannis DP (2001) Infectious complications of purine analog therapy. Curr Opin Infect Dis 14:409–413

    PubMed  CAS  Google Scholar 

  192. Wadhwa PD, Morrison VA (2006) Infectious complications of chronic lymphocytic leukemia. Semin Oncol 33:240–249

    PubMed  CAS  Google Scholar 

  193. Berkey P, Bodey GP (1989) Nocardial infection in patients with neoplastic disease. Rev Infect Dis 11:407–412

    PubMed  CAS  Google Scholar 

  194. Kontoyiannis DP, Ruoff K, Hooper DC (1998) Nocardia bacteremia. Report of 4 cases and review of the literature. Medicine (Baltimore) 77:255–267

    CAS  Google Scholar 

  195. Kontoyiannis DP, Jacobson KL, Whimbey EE, Rolston KV, Raad II (2000) Central venous catheter-associated Nocardia bacteremia: an unusual manifestation of nocardiosis. Clin Infect Dis 31(2):617–618

    PubMed  CAS  Google Scholar 

  196. Christidou A, Maraki S, Scoulica E, Mantadakis E, Agelaki S, Samonis G (2004) Fatal Nocardia farcinica bacteremia in a patient with lung cancer. Diagn Microbiol Infect Dis 50:135–139

    PubMed  Google Scholar 

  197. McNeil MM, Brown JM, Georghiou PR, Allworth AM, Blacklock ZM (1992) Infections due to Nocardia transvalensis: clinical spectrum and antimicrobial therapy. Clin Infect Dis 15:453–463

    PubMed  CAS  Google Scholar 

  198. Elsayed S, Kealey A, Coffin CS, Read R, Megran D, Zhang K (2006) Nocardia cyriacigeorgica septicemia. J Clin Microbiol 44:280–282

    PubMed  Google Scholar 

  199. Ansari SR, Safdar A, Han XY, O’Brien S (2006) Nocardia veterana bloodstream infection in a patient with cancer and a summary of reported cases. Int J Infect Dis 10:483–486

    PubMed  Google Scholar 

  200. Sorrell TC, Mitchell DH, Iredell JR (2005) Nocardia. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases, 6th edn. Elsevier Churchill Livingston, Philadelphia, PA, pp 2916–2924

    Google Scholar 

  201. Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW, Wallace RJ Jr (2001) In vitro activities of linezolid against multiple Nocardia species. Antimicrob Agents Chemother 45:1295–1297

    PubMed  CAS  Google Scholar 

  202. Clinical and Laboratory Standards Institute. M-24 – Susceptibility testing of mycobacteria, nocardia and other aerobic actinomycetes. Catalog 2-2007.

    Google Scholar 

  203. Gombert ME, Aulicino TM (1983) Synergism of imipenem and amikacin in combination with other antibiotics against Nocardia asteroides. Antimicrob Agents Chemother 24:810–811

    PubMed  CAS  Google Scholar 

  204. Moylett EH, Pacheco SE, Brown-Elliott BA et al (2003) Clinical experience with linezolid for the treatment of nocardia infection. Clin Infect Dis 36:313–318

    PubMed  CAS  Google Scholar 

  205. Rupprecht TA, Pfister HW (2005) Clinical experience with linezolid for the treatment of central nervous system infections. Eur J Neurol 12:536–542

    PubMed  CAS  Google Scholar 

  206. Lerner PI (1996) Nocardiosis. Clin Infect Dis 22:891–903 quiz 4-5

    PubMed  CAS  Google Scholar 

  207. Boiron P, Provost F, Chevrier G, Dupont B (1992) Review of nocardial infections in France 1987 to 1990. Eur J Clin Microbiol Infect Dis 11:709–714

    PubMed  CAS  Google Scholar 

  208. Ortbals DW, Marr JJ (1978) A comparative study of tuberculous and other mycobacterial infections and their associations with malignancy. Am Rev Respir Dis 117:39–45

    PubMed  CAS  Google Scholar 

  209. Feld R, Bodey GP, Groschel D (1976) Mycobacteriosis in patients with malignant disease. Arch Intern Med 136:67–70

    PubMed  CAS  Google Scholar 

  210. Kaplan MH, Armstrong D, Rosen P (1974) Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer 33:850–858

    PubMed  CAS  Google Scholar 

  211. Yuen KY, Woo PC (2002) Tuberculosis in blood and marrow transplant recipients. Hematol Oncol 20:51–62

    PubMed  CAS  Google Scholar 

  212. De La Rosa GR, Jacobson KL, Rolston KV, Raad II, Kontoyiannis DP, Safdar A (2004) Mycobacterium tuberculosis at a comprehensive cancer centre: active disease in patients with underlying malignancy during 1990–2000. Clin Microbiol Infect 10:749–752

    Google Scholar 

  213. Kamboj M, Sepkowitz KA (2006) The risk of tuberculosis in patients with cancer. Clin Infect Dis 42:1592–1595

    PubMed  Google Scholar 

  214. Libshitz HI, Pannu HK, Elting LS, Cooksley CD (1997) Tuberculosis in cancer patients: an update. J Thorac Imaging 12:41–46

    PubMed  CAS  Google Scholar 

  215. Centers for Disease Control and Prevention (2006) Reported Tuberculosis in the United States, 2005. U.S. Department of Health and Human Services, CDC, Atlanta, GA. http://www.cdc.gov/tb/. Accessed Sept 2006

  216. de la Camara R, Martino R, Granados E et al (2000) Tuberculosis after hematopoietic stem cell transplantation: incidence, clinical characteristics and outcome. Spanish Group on Infectious Complications in Hematopoietic Transplantation. Bone Marrow Transplant 26:291–298

    PubMed  Google Scholar 

  217. Leung WH, Tsang SF, Chim CS (2005) Extrapulmonary tuberculous abscess in chronic lymphocytic leukaemia (CLL) treated with fludarabine: case report and review of literature. Am J Hematol 79:246–247

    PubMed  CAS  Google Scholar 

  218. Abad S, Gyan E, Moachon L et al (2003) Tuberculosis due to Mycobacterium bovis after alemtuzumab administration. Clin Infect Dis 37:e27–e28

    PubMed  CAS  Google Scholar 

  219. Wendtner CM, Ritgen M, Schweighofer CD et al (2004) Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission–experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18:1093–1101

    PubMed  CAS  Google Scholar 

  220. Crum NF, Lederman ER, Wallace MR (2005) Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84:291–302

    CAS  Google Scholar 

  221. Aisenberg GM, Jacobson K, Chemaly RF, Rolston KV, Raad II, Safdar A (2005) Extrapulmonary tuberculosis active infection misdiagnosed as cancer: Mycobacterium tuberculosis disease in patients at a Comprehensive Cancer Center (2001–2005). Cancer 104:2882–2887

    PubMed  Google Scholar 

  222. Choksey MS, Powell M, Gibb WR, Casey AT, Geddes JF (1989) A conus tuberculoma mimicking an intramedullary tumour: a case report and review of the literature. Br J Neurosurg 3:117–121

    PubMed  CAS  Google Scholar 

  223. Wu CS, Wang SH, Kuo TT (1994) Pancreatic tuberculosis mimicking pancreatic head carcinoma: a case report and review of the literature. Infection 22:287–289

    PubMed  CAS  Google Scholar 

  224. Rezeig MA, Fashir BM, Al-Suhaibani H, Al-Fadda M, Amin T, Eisa H (1998) Pancreatic tuberculosis mimicking pancreatic carcinoma: four case reports and review of the literature. Dig Dis Sci 43:329–331

    PubMed  CAS  Google Scholar 

  225. Piura B, Rabinovich A, Leron E, Yanai-Inbar I, Mazor M (2002) Peritoneal tuberculosis mimicking ovarian carcinoma with ascites and elevated serum CA-125: case report and review of literature. Eur J Gynaecol Oncol 23:120–122

    PubMed  CAS  Google Scholar 

  226. Comert FB, Comert M, Kulah C, Tascilar O, Numanoglu G, Aydemir S (2006) Colonic tuberculosis mimicking tumor perforation: a case report and review of the literature. Dig Dis Sci 51:1039–1042

    PubMed  Google Scholar 

  227. Koc S, Beydilli G, Tulunay G et al (2006) Peritoneal tuberculosis mimicking advanced ovarian cancer: a retrospective review of 22 cases. Gynecol Oncol 103:565–569

    PubMed  Google Scholar 

  228. Malone JL, Ijaz K, Lambert L et al (2004) Investigation of healthcare-associated transmission of Mycobacterium tuberculosis among patients with malignancies at three hospitals and at a residential facility. Cancer 101:2713–2721

    PubMed  Google Scholar 

  229. Anon (2005) Management of a tuberculosis exposure in an oncology hospital. Can Commun Dis Rep 31:149–156

    Google Scholar 

  230. Menzies D, Pai M, Comstock G (2007) Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 146:340–354

    PubMed  Google Scholar 

  231. Kim DK, Lee SW, Yoo CG et al (2005) Clinical characteristics and treatment responses of tuberculosis in patients with malignancy receiving anticancer chemotherapy. Chest 128:2218–2222

    PubMed  CAS  Google Scholar 

  232. Iseman MD (2000) A clinician’s guide to tuberculosis. Lippincott Williams and Wilkins, Philadelphia, PA, p 134

    Google Scholar 

  233. Fujii H, Ishihara J, Fukaura A et al (1992) Early diagnosis of tuberculosis by fiberoptic bronchoscopy. Tuber Lung Dis 73:167–169

    PubMed  CAS  Google Scholar 

  234. Baughman RP, Dohn MN, Loudon RG, Frame PT (1991) Bronchoscopy with bronchoalveolar lavage in tuberculosis and fungal infections. Chest 99:92–97

    PubMed  CAS  Google Scholar 

  235. Woods GL (2001) Molecular techniques in myobacterial detection. Arch Pathol Lab Med 125:122–126

    PubMed  CAS  Google Scholar 

  236. Palomino JC (2005) Nonconventional and new methods in the diagnosis of tuberculosis: feasibility and applicability in the field. Eur Respir J 26:339–350

    PubMed  CAS  Google Scholar 

  237. Kang EY, Choi JA, Seo BK, Oh YW, Lee CK, Shim JJ (2002) Utility of polymerase chain reaction for detecting Mycobacterium tuberculosis in specimens from percutaneous transthoracic needle aspiration. Radiology 225:205–209

    PubMed  CAS  Google Scholar 

  238. Centers for Disease Control and Prevention (2005) National plan for reliable tuberculosis laboratory services using a systems approach: recommendations from CDC and the Association of Public Health Laboratories Task Force on Tuberculosis. Laboratory Services. MMWR 54:RR-6

    Google Scholar 

  239. Rattan A, Kalia A, Ahmad N (1998) Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg Infect Dis 4:195–209

    PubMed  CAS  Google Scholar 

  240. Tenover FC (2007) Rapid detection and identification of bacterial pathogens using novel molecular technologies: infection control and beyond. Clin Infect Dis 44:418–423

    PubMed  CAS  Google Scholar 

  241. Li X, Zhang Y, Shen X et al (2007) Transmission of drug-resistant tuberculosis among treated patients in Shanghai, China. J Infect Dis 195:864–869

    PubMed  Google Scholar 

  242. Centers for Disease Control and Prevention (2000) Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. MMWR 49:RR06

    Google Scholar 

  243. Centers for Disease Control and Prevention (2003) Update: adverse event data revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection – United States, 2003. MMWR 52(31):735–738

    Google Scholar 

  244. Wallace RJ Jr, Swenson JM, Silcox VA, Good RC, Tschen JA, Stone MS (1983) Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis 5:657–679

    PubMed  Google Scholar 

  245. Rolston KV, Jones PG, Fainstein V, Bodey GP (1985) Pulmonary disease caused by rapidly growing mycobacteria in patients with cancer. Chest 87:503–506

    PubMed  CAS  Google Scholar 

  246. Jacobson K, Garcia R, Libshitz H et al (1998) Clinical and radiological features of pulmonary disease caused by rapidly growing mycobacteria in cancer patients. Eur J Clin Microbiol Infect Dis 17:615–621

    PubMed  CAS  Google Scholar 

  247. Kiehn TE, Edwards FF, Brannon P et al (1985) Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics. J Clin Microbiol 21:168–173

    PubMed  CAS  Google Scholar 

  248. Han XY, Tarrand JJ, Infante R, Jacobson KL, Truong M (2005) Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare among patients without AIDS. J Clin Microbiol 43:4407–4412

    PubMed  Google Scholar 

  249. Golomb HM, Hadad LJ (1984) Infectious complications in 127 patients with hairy cell leukemia. Am J Hematol 16:393–401

    PubMed  CAS  Google Scholar 

  250. Bennett C, Vardiman J, Golomb H (1986) Disseminated atypical mycobacterial infection in patients with hairy cell leukemia. Am J Med 80:891–896

    PubMed  CAS  Google Scholar 

  251. Thaker H, Neilly IJ, Saunders PG, Magee JG, Snow MH, Ong EL (2001) Remember mycobacterial disease in hairy cell leukaemia (HCL). J Infect 42:213–214

    PubMed  CAS  Google Scholar 

  252. Jacobson KL, Teira R, Libshitz HI et al (2000) Mycobacterium kansasii infections in patients with cancer. Clin Infect Dis 31:628–631

    PubMed  CAS  Google Scholar 

  253. Shah MK, Sebti A, Kiehn TE, Massarella SA, Sepkowitz KA (2001) Mycobacterium haemophilum in immunocompromised patients. Clin Infect Dis 33:330–337

    PubMed  CAS  Google Scholar 

  254. Saubolle MA, Kiehn TE, White MH, Rudinsky MF, Armstrong D (1996) Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Clin Microbiol Rev 9:435–447

    PubMed  CAS  Google Scholar 

  255. Vos MC, de Haas PE, Verbrugh HA et al (2003) Nosocomial Mycobacterium bovis-bacille Calmette-Guerin infections due to contamination of chemotherapeutics: case finding and route of transmission. J Infect Dis 188:1332–1335

    PubMed  Google Scholar 

  256. Engervall P, Bjorkholm M, Petrini B, Heurlin N, Henriques B, Kallenius G (1993) Disseminated Mycobacterium malmoense infection in a patient with chronic granulocytic leukaemia. J Intern Med 234:231–233

    PubMed  CAS  Google Scholar 

  257. Castor B, Juhlin I, Henriques B (1994) Septic cutaneous lesions caused by Mycobacterium malmoense in a patient with hairy cell leukemia. Eur J Clin Microbiol Infect Dis 13:145–148

    PubMed  CAS  Google Scholar 

  258. Enzensberger R, Hunfeld KP, Elshorst-Schmidt T, Boer A, Brade V (2002) Disseminated cutaneous Mycobacterium marinum infection in a patient with non-Hodgkin’s lymphoma. Infection 30:393–395

    PubMed  CAS  Google Scholar 

  259. Hachem R, Raad I, Rolston KV et al (1996) Cutaneous and pulmonary infections caused by Mycobacterium vaccae. Clin Infect Dis 23:173–175

    PubMed  CAS  Google Scholar 

  260. Akiyama H, Maruyama T, Uetake T, Kawaguchi K, Sakamaki H, Onozawa Y (1991) Systemic infection due to atypical mycobacteria in patients with chronic myelogenous leukemia. Rev Infect Dis 13:815–818

    PubMed  CAS  Google Scholar 

  261. Hoy JF, Rolston KV, Hopfer RL, Bodey GP (1987) Mycobacterium fortuitum bacteremia in patients with cancer and long-term venous catheters. Am J Med 83:213–217

    PubMed  CAS  Google Scholar 

  262. Raad II, Vartivarian S, Khan A, Bodey GP (1991) Catheter-related infections caused by the Mycobacterium fortuitum complex: 15 cases and review. Rev Infect Dis 13:1120–1125

    PubMed  CAS  Google Scholar 

  263. Kline S, Cameron S, Streifel A et al (2004) An outbreak of bacteremias associated with Mycobacterium mucogenicum in a hospital water supply. Infect Control Hosp Epidemiol 25:1042–1049

    PubMed  Google Scholar 

  264. Lee SA, Raad II, Adachi JA, Han XY (2004) Catheter-related bloodstream infection caused by Mycobacterium brumae. J Clin Microbiol 42:5429–5431

    PubMed  Google Scholar 

  265. Oh WS, Ko KS, Song JH et al (2005) Catheter-associated bacteremia by Mycobacterium senegalense in Korea. BMC Infect Dis 5:107

    PubMed  Google Scholar 

  266. Perandin F, Pinsi G, Signorini L, Soavi L, Signorini C, Manca N (2006) Mycobacterium szulgai identification by hsp65 gene sequencing in an HIV-positive patient with non-Hodgkin’s lymphoma. New Microbiol 29:215–218

    PubMed  Google Scholar 

  267. Doucette K, Fishman JA (2004) Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 38:1428–1439

    PubMed  Google Scholar 

  268. Gaviria JM, Garcia PJ, Garrido SM, Corey L, Boeckh M (2000) Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. Biol Blood Marrow Transplant 6:361–369

    PubMed  CAS  Google Scholar 

  269. Weinstock DM, Feinstein MB, Sepkowitz KA, Jakubowski A (2003) High rates of infection and colonization by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 31:1015–1021

    PubMed  CAS  Google Scholar 

  270. (1997) Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 156:S1–S25

    Google Scholar 

  271. Goldstein EJ (1996) Anaerobic bacteremia. Clin Infect Dis 23(Suppl 1):S97–S101

    PubMed  Google Scholar 

  272. Lark RL, McNeil SA, VanderHyde K, Noorani Z, Uberti J, Chenoweth C (2001) Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis 33:338–343

    PubMed  CAS  Google Scholar 

  273. Zahar JR, Farhat H, Chachaty E, Meshaka P, Antoun S, Nitenberg G (2005) Incidence and clinical significance of anaerobic bacteraemia in cancer patients: a 6-year retrospective study. Clin Microbiol Infect 11:724–729

    PubMed  Google Scholar 

  274. Noriega LM, Van der Auwera P, Phan M et al (1993) Anaerobic bacteremia in a cancer center. Support Care Cancer 1:250–255

    PubMed  CAS  Google Scholar 

  275. Martino R, Ramila E, Capdevila JA et al (2001) Bacteremia caused by Capnocytophaga species in patients with neutropenia and cancer: results of a multicenter study. Clin Infect Dis 33:E20–E22

    PubMed  CAS  Google Scholar 

  276. Maury S, Leblanc T, Rousselot P, Legrand P, Arlet G, Cordonnier C (1999) Bacteremia due to Capnocytophaga species in patients with neutropenia: high frequency of beta-lactamase-producing strains. Clin Infect Dis 28:1172–1174

    PubMed  CAS  Google Scholar 

  277. Roscoe DL, Zemcov SJ, Thornber D, Wise R, Clarke AM (1992) Antimicrobial susceptibilities and beta-lactamase characterization of Capnocytophaga species. Antimicrob Agents Chemother 36:2197–2200

    PubMed  CAS  Google Scholar 

  278. Yadegarynia D, Tarrand J, Raad I, Rolston K (2003) Good interpretation of the results of a diagnostic test. Reply to correspondence. Clin Infect Dis 37:1144–1145

    PubMed  CAS  Google Scholar 

  279. Elting LS, Bodey GP, Fainstein V (1986) Polymicrobial septicemia in the cancer patient. Medicine (Baltimore) 65:218–225

    CAS  Google Scholar 

  280. Rolston KV (2005) Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 40(Suppl 4):S246–S252

    PubMed  Google Scholar 

  281. Giamarellou H, Bassaris HP, Petrikkos G, Busch W, Voulgarelis M, Antoniadou A, Grouzi E, Zoumbos N (2000) Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrob Agents Chemother 44(12):3264–3271

    PubMed  CAS  Google Scholar 

  282. Harter C, Schulze B, Goldschmidt H, Benner A, Geiss HK, Hoppe-Tichy T, Ho AD, Egerer G (2006) Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant 37(4):373–379

    PubMed  CAS  Google Scholar 

  283. Del Favero A, Menichetti F, Martino P, Bucaneve G, Micozzi A, Gentile G, Furno P, Russo D, D’Antonio D, Ricci P, Martino B, Mandelli F, Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program (2001) A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 33(8):1295–1301

    PubMed  Google Scholar 

  284. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Granena A, Gudiol F (1996) Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 15:291–296

    PubMed  CAS  Google Scholar 

  285. Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, Bucaneve G, Crokaert F, Kern WV, Klastersky J, Langenaeken I, Micozzi A, Padmos A, Paesmans M, Viscoli C, Glauser MP (1996) Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto Infection Program. Antimicrob Agents Chemother 40(5):1108–1115

    PubMed  CAS  Google Scholar 

  286. Gorschlüter M, Mey U, Strehl J, Ziske C, Schepke M, Schmidt-Wolf IG, Sauerbruch T, Glasmacher A (2005) Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol 75(1):1–13

    PubMed  Google Scholar 

  287. Gomez L, Martino R, Rolston KV (1998) Neutropenic enterocolitis: spectrum of the disease and comparison of definite and possible cases. Clin Infect Dis 27(4):695–699

    PubMed  CAS  Google Scholar 

  288. Jones GT, Abramson N (1983) Gastrointestinal necrosis in acute leukemia: a complication of induction therapy. Cancer Invest 1(4):315–320

    PubMed  CAS  Google Scholar 

  289. Khardori N, Wong E, Carrasco CH, Wallace S, Patt Y, Bodey GP (1991) Infections associated with biliary drainage procedures in patients with cancer. Rev Infect Dis 13(4):587–591

    PubMed  CAS  Google Scholar 

  290. Stender H (2003) PNA FISH: an intelligent stain for rapid diagnosis of infectious diseases. Expert Rev Mol Diagn 3:649–655

    PubMed  CAS  Google Scholar 

  291. Hartmann H, Stender H, Schafer A, Autenrieth IB, Kempf VA (2005) Rapid identification of Staphylococcus aureus in blood cultures by a combination of fluorescence in situ hybridization using peptide nucleic acid probes and flow cytometry. J Clin Microbiol 43:4855–4857

    PubMed  CAS  Google Scholar 

  292. Forrest GN, Mehta S, Weekes E, Lincalis DP, Johnson JK, Venezia RA (2006) Impact of rapid in situ hybridization testing on coagulase-negative staphylococci positive blood cultures. J Antimicrob Chemother 58:154–158

    PubMed  CAS  Google Scholar 

  293. Forrest GN (2007) PNA FISH: present and future impact on patient management. Expert Rev Mol Diagn 7:231–236

    PubMed  CAS  Google Scholar 

  294. Alexander BD, Ashley ED, Reller LB, Reed SD (2006) Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. Diagn Microbiol Infect Dis 54:277–282

    PubMed  CAS  Google Scholar 

  295. Toombs LS, Forrest GN, Weekes E, Lincalis DP, Johnson JK, Venezia RA (2006) Impact of peptide nucleic acid (PNA) fluorescence in situ hybridization (FISH) for enterococcal blood stream infections. In: Infectious Diseases Society of America Meeting, Toronto, Canada, 12–15 October 2006

    Google Scholar 

  296. Xu J, Moore JE, Millar BC et al (2004) Improved laboratory diagnosis of bacterial and fungal infections in patients with hematological malignancies using PCR and ribosomal RNA sequence analysis. Leuk Lymphoma 45:1637–1641

    PubMed  CAS  Google Scholar 

  297. Ruokonen E, Nousiainen T, Pulkki K, Takala J (1999) Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis 18:283–285

    PubMed  CAS  Google Scholar 

  298. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A et al (2004) Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 23:539–544

    Google Scholar 

  299. Yonemori K, Kanda Y, Yamamoto R et al (2001) Clinical value of serial measurement of serum C-reactive protein level in neutropenic patients. Leuk Lymphoma 41:607–614

    PubMed  CAS  Google Scholar 

  300. Maki DG, Weise CE, Sarafin HW (1977) A semiquantitative culture method for identifying intravenous-catheter-related infection. N Engl J Med 296(23):1305–1309

    PubMed  CAS  Google Scholar 

  301. Raad I, Hanna HA, Alakech B, Chatzinikolaou I, Johnson MM, Tarrand J (2004) Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med 140:18–25

    PubMed  Google Scholar 

  302. Blot F, Nitenberg G, Chachaty E et al (1999) Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet 354:1071–1077

    PubMed  CAS  Google Scholar 

  303. Malgrange VB, Escande MC, Theobald S (2001) Validity of earlier positivity of central venous blood cultures in comparison with peripheral blood cultures for diagnosing catheter-related bacteremia in cancer patients. J Clin Microbiol 39:274–278

    PubMed  CAS  Google Scholar 

  304. Mermel LA, Farr BM, Sherertz RJ et al (2001) Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 32:1249–1272

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Infectious Diseases, Barbara Ann Karmanos Cancer Institute, Wayne State University, and Harper University Hospital, Detroit, MI, USA

    Pranatharthi H. Chandrasekar M.D. & George Alangaden M.D.

Authors
  1. Pranatharthi H. Chandrasekar M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Alangaden M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pranatharthi H. Chandrasekar M.D. .

Editor information

Editors and Affiliations

  1. School of Medicine, University of Maryland, S. Greene St. 22, Baltimore, 21201, U.S.A.

    Michael Kleinberg

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press

About this chapter

Cite this chapter

Chandrasekar, P.H., Alangaden, G. (2009). Bacteria. In: Kleinberg, M. (eds) Managing Infections in Patients With Hematological Malignancies. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-415-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-415-5_3

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-986-4

  • Online ISBN: 978-1-59745-415-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation